Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
World’s first regenerative product for heart failure

Celyad developed a breakthrough Cardiopoiesis platform designed to differentiate stem cells into cardiac cells to treat heart failure and acute my…


TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction

TiGenix, stem cell specialist focused on developing novel therapeutics from its two proprietary platforms of donor-derived expanded adipose derive…

POPULAR TAGS

Celyad's cardiac stem cell treatment fails phase III clinical trials

Written by DS on in the category news with the tags , .


Celyad’s cardiac therapy C-Cure® failed to show a significant benefit in the CHART-1 phase III clinical study. C-Cure is an experimental treatment based on stem cells that produce new autologous heart muscle cells, which behave identically to those lost during infarction. Although the clinical endpoint was not reached for the entire study population, a significant benefit was observed in a subgroup representing 60% of the study’s population.

Dr. Christian Homsy, CEO of Celyad, commented: “For the first time in a randomized, double-blind, controlled, Phase III cell therapy study, a positive effect, consistent across all parameters tested, was observed for a substantial, clearly definable, group of heart failure patients. CHART-1 has allowed us to better define the patient population that would benefit from C-Cure®."

Celyad will contact the European Medicine Agency concerning a marketing authorization application, based on the positive results seen in the highly clinically relevant group of patients. The company is now looking for a partnership to further develop and commercialize C-Cure®.

Investors responded firmly to the news, with Celyad shares shedding 40% of their value. Luckily, Celyad still has its promising immune-oncology platform to soften the blow of the now failed cardiology branch. All eyes are now on the company’s CAR-T technology.

RELATED ARTICLES
World’s first regenerative product for heart failure

Celyad developed a breakthrough Cardiopoiesis platform designed to differentiate stem cells into cardiac cells to treat heart failure and acute my…


TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction

TiGenix, stem cell specialist focused on developing novel therapeutics from its two proprietary platforms of donor-derived expanded adipose derive…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Biowin Turnstone XpandInnovation Itera Life Science KU Leuven Janssen V-Bio Ventures Flanders.bio UGent GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.